Advanced or Metastatic NRAS-mutant Melanoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Erasca
ErascaSAN DIEGO, CA
1 program
1
NaporafenibPhase 3Small Molecule1 trial
Active Trials
NCT06346067Active Not RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
ErascaNaporafenib

Clinical Trials (1)

NCT06346067ErascaNaporafenib

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Start: Apr 2024Est. completion: Dec 2028
Phase 3Active Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
15m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)